Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.
暂无分享,去创建一个
M. Gleave | S. Goldenberg | N. Bruchovsky | L. Sullivan | K. Akakura | S. Goldenberg | S L Goldenberg | N Bruchovsky | M E Gleave | L D Sullivan | K Akakura
[1] J. Foekens,et al. Relative effectiveness of alternative androgen withdrawal therapies in initiating regression of rat prostate. , 1988, Journal of Urology.
[2] L. Klotz,et al. Intermittent endocrine therapy for advanced prostate cancer , 1986, Cancer.
[3] M. Soloway,et al. Prognostic significance of changes in prostate‐specific markers after endocrine treatment of stage D2 prostatic cancer , 1992, Cancer.
[4] T. Maatman. The role of prostate specific antigen as a tumor marker in men with advanced adenocarcinoma of the prostate. , 1989, The Journal of urology.
[5] S. Goldenberg,et al. Effects of intermittent androgen suppression on androgen‐dependent tumors. Apoptosis and serum prostate‐specific antigen , 1993, Cancer.
[6] S. Goldenberg,et al. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma. , 1988, The Journal of urology.
[7] P. Goodman,et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.
[8] J. Miller,et al. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. , 1992, The Journal of urology.
[9] S. Goldenberg,et al. Use of cyproterone acetate in prostate cancer. , 1991, The Urologic clinics of North America.
[10] A. Coldman,et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. , 1990, Cancer research.
[11] N. Bruchovsky,et al. Luteinizing hormone‐releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low‐dose diethylstilbestrol , 1993, Cancer.